Search results

Master’s programme in International Marketing and Brand Management – Statement of purpose, year 2024/2025 1/42023-10-16 Master’s programme in International Marketing and Brand Management STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plican

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20IMBM%20LUSEM.pdf - 2025-11-10

Master’s programme in Management – Statement of purpose, year 2024/2025 1/32023-10-16 Master’s programme in Management STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plicants to our programmes. Your statement of purpose needs to reflect who

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20Management%20LUSEM.pdf - 2025-11-10

Master’s programme in Economic Growth, Population and Development – Statement of purpose, year 2024/2025 1/42023-10-13 Master’s programme in Global Development, Population and Economic Change STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- p

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20global-dev%20LUSEM.pdf - 2025-11-10

Master’s programme in Information Systems – Statement of purpose, year 2024/2025 1/32023-10-16 Master’s programme in Information Systems STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plicants to our programmes. Your statement of purpose ne

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20info-systems%20LUSEM.pdf - 2025-11-10

Master’s programme in International Strategic Management – Statement of purpose, year 2024/2025 1/42023-10-16 Master’s programme in International Strategic Management STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plicants to our programmes

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20int-strat-man%20LUSEM.pdf - 2025-11-10

Master’s programme in Managing People, Knowledge and Change – Statement of purpose, year 2024/2025 1/42023-10-16 Master’s programme in Managing People, Knowledge and Change STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plicants to our prog

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20mpkc%20LUSEM.pdf - 2025-11-10

Master’s programme in European and International Trade and Tax Law – Statement of purpose, year 2024/2025 1/32023-10-16 Master’s programme in European and International Trade and Tax Law STATEMENT OF PURPOSE | YEAR 2025/2026 The statement of purpose is one of the most important, and challenging, elements of your application. It is your opportunity to stand out from the hundreds of other ap- plican

https://www.lusem.lu.se/sites/lusem.lu.se/files/2024-10/Statement%20of%20purpose%202025-26%20trade-tax-law%20LUSEM.pdf - 2025-11-10

Magisterprogram i dataanalys och ekonomi Kurslitteratur – HT2025/VT2026 MSc in Data Analytics and Business Economics Literature – autumn term 2025/spring term 2026 DABN13 Machine Learning from a Regression Perspective Lindholm, A., Wahlström, N., Lindsten, F., & Schön, T. B. (2022): Machine Learning: A First Course for Engineers and Scientists. Cambridge University Press. James, G., Witten, D., Ha

https://www.lusem.lu.se/sites/lusem.lu.se/files/2025-06/Litteratur-DABE-ht25-vt26.pdf - 2025-11-10

Mot smartare cellgiftsbehandling: Att förebygga behandlingsresistens vid äggstockscancer Äggstockscancer är den dödligaste gynekologiska cancertypen och kräver alltför många liv eftersom tumörer ofta blir resistenta mot behandling – särskilt mot cisplatin, vårt främsta försvar. För att rädda fler liv måste vi förstå hur denna resistens utvecklas och hur vi kan överlista den. I mitt examensarbete Ovarian cancer is the deadliest gynaecologic malignancy, with most patients diagnosed at an advanced stage and facing poor long-term survival. Resistance to cisplatin-based chemotherapy is a major clinical obstacle, yet its proteomic drivers remain poorly defined. In this study, I applied data-independent acquisition mass spectrometry with DIA-NN data processing to analyse one parental and two cis

Background Anti-interleukin (IL)-4Rα monoclonal antibodies (mAb) improve lung function and decreasethe number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement ofearly innate immune responses underlying these treatment effects is not well known. We sought tounderstand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells (BECs) fromCBackgroundAnti-IL-4Rα monoclonal antibodies (mAb) improve lung function and decrease the number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement of early innate immune responses underlying these treatment effects is not well known. We sought to understand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells from COPD patients under

Background. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 effic